OMX Ventures

Navigare Ventures is an early-stage investor specialized in science-driven companies. Through our investments, we strengthen the industrial and societal impact of research, as well as the long-term financial capacity of our owners, Wallenberg Investments AB. Our core investment themes within deep tech are underpinned by our knowledge and network in a number of scientific fields and industries. These include advanced computing and quantum technologies, synthetic biology and bio innovation, advanced materials and nano technology as well as data-driven life science. We are long term investors - Seed and Series A and beyond - and form deep and lasting partnerships with founders and entrepreneurs. Our extensive industrial and scientific networks gives us the opportunity to provide capital, network, and know-how to transform promising science start-ups into successful companies. Who we are Navigare Ventures, based in Stockholm, is a fully owned subsidiary of Wallenberg Investments AB. We are a team of scientists, industrialists and entrepreneurs who understand the challenges of turning cutting-edge technologies to successful ventures. As part of the Wallenberg ecosystem, our returns fuel the next generation of scientific advancement through research funding from the Wallenberg Foundations to Swedish universities. What we are looking for We partner with experienced entrepreneurial teams that combine scientific excellence with strong business acumen. In this respect, your company should have a unique offering based on a profound understanding of your scientific or technological field and its market and industrial environment. You should also be capable of demonstrating the viability and commercial potential of your product by engaging with real customers. You are raising capital to scale the R&D, production, marketing, and sales capabilities of your company. Our investment philosophy We only invest in companies we understand. While this is an important general principle in any investment activity, it is even more important when making early-stage investments in new technology. If we don’t understand your science, we won’t understand what experts tell us about the value chain and how it works, or what the competitive landscape looks like. And most importantly, we won’t be able to help you develop your strategy and navigate through the challenges of deep-tech start-ups. So, when preparing a meeting with us, don’t put too much emphasis on future revenue projections. That’s important too, in due time. But first, be prepared for long sessions in front of a whiteboard, explaining to us how your material, algorithm, or antibody functions. We don’t need to understand all the equations, but we need to get the heuristics. We are scientists at heart, eager to learn, and we carry a deep conviction that the world is fundamentally understandable. Core investment themesAdvanced computing and quantum technologies: Digitization and automation deepens in industry and society, driven by breakthroughs in computing and AI. Our focus includes improving existing technologies as well as finding completely new platforms in AI and other areas of applied mathematics as well as in novel computer architectures, communication technology, hardware and design. Synthetic biology and bio innovation: Synthetic biology and bio innovations contribute to a more sustainable society. Companies in this field often combine principles of biology, engineering, and computer science for the development of new biological products and manufacturing methods. Advanced materials and nano technology: New materials and nanoscale technology enable disruptions with the potential to benefit numerous existing industries. From quantum materials to biomaterials and biologically inspired nanostructures, we look for the most promising technology platforms in the field. Data-driven life science: Combining digital technology and data with life science drives scientific understanding and enables novel products. Our focus is on data-driven methods to increase personalization and precision of medical interventions, accelerate product development, digitalize care among other advancements.

AI acceleration of scientific innovation and commercialization. Life Extension ventures invests in the two largest sectors in the world, People and Planet, where AI suddenly matters. Novel commercialization through marketplaces, networks, Web3, personalizations, payments, APIs, new go-to-markets and operations. Software, AI, and the power of the Internet will accelerate the adoption and monetization of science breakthroughs on human and planetary life. New infrastructure like SaaS, data platforms, OSs, LLMs, collaboration tools, storage, simulations, GenAI, visualization tools, security, workflow automation, Web3 and DAOs, or design tools to accelerate innovations. We target the infrastructure that accelerates the innovations. Software and AI are reinventing many industries bringing benefits to society and creating new category defining multibillion dollar companies; and now is the turn of climate, biology and health.

Our planet is facing a multitude of urgent challenges; from climate change, dwindling natural resources and rapid urbanisation, to a growing demand for accessible healthcare. These pressing issues call for innovative and sustainable solutions that only scientific advancements can provide. Deep Science as an Asset Class.We invest in scientific breakthroughs that together advance human capability and create financial returns. We’re looking for: Entirely new technologies developed from fundamental research IP-rich innovations with competitive defensibility Solutions to real problems in Life Sciences, Advanced Materials, TechBio, Photonics and Quantum Hardware, Robotics and Automation, AgChem/Tech and DeepTech We offer portfolio exposure to deep science investments supported by a best-in-class due diligence process conducted by experienced entrepreneurs, operators, investors and scientists Investing with Empirical Ventures. ACCESS: leading pre-seed and seed rounds by leveraging our market-leading due diligence and domain expertise, opening doors to the best deals and co-investors SELECTION: our robust, highly selective process identifies cutting-edge scientific advances from the UK R&D landscape with the most compelling commercial opportunities SCALE: Our track record presents unparalleled opportunities to scale our portfolio companies and attract the best follow-on investors and talent POSITION: Our approach increases the probability of reaching Series A, a key inflection point for pre-seed and seed investors.

Vsquared Ventures backs entrepreneurs engineering the seemingly impossible. We are early-stage investors in deep-tech companies tackling society's most pressing challenges, with an emphasis on quantum and novel computing, green energy, robotics, Al/ML, new space, synthetic biology, and healthcare. Our team of founders, academics, operators and innovators has invested in over 30 companies to date and built one of Europe's strongest deep-tech portfolios, forging alliances with key players in industry, research, and a global startup ecosystem along the way. The companies we've partnered with so far include Isar Aerospace, IOM, Zama, The Exploration Company, and Custom Cells.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

SeaX Ventures is a venture capital fund investing globally in early-stage companies with groundbreaking “exponential” technologies. We support visionary entrepreneurs across the world on their journeys to build great companies. We invest everywhere In the U.S. In Southeast Asia. Everywhere that founders are working on great ideas, we’ll be there. Centered on South East Asia expansion Our LPs consist of a few of the largest corporations in the region. We work with them strategically by making connections to the innovative entrepreneurs in whose startups we invest. That way, both our portfolio companies and our corporate partners benefit. Our unique 3As approachAccess: We provide our LPs access to deal flow globally with a focus on the U.S. and Asia. Accelerate: We leverage the platforms and networks of our sister company (RISE) which has over 2000+ startup alumni across the U.S. and Asia and several hundred corporate partners. Advantage: Our LPs are top multinational corporations and family offices. Collectively, we are a network of entrepreneurs, business partners, and co-investors. Bridging Silicon Valley and Asia Our knowledge of markets in both the US and Asia empowers us to identify and assist founders building audacious companies. Our focus is deep-tech We focus on exponential technologies that can transform societies and help countries achieve high levels of economic progress. So far, we’ve invested in Web3, biotech, advanced materials, and AI but we are certainly not limited to those areas. We’re also looking to support groundbreaking companies in agriculture, space, robotics, and more. Healthcare / Biotech Web3 / Crypto Material Science / Nanotechnology Artificial Intelligence Hardware / Robotics Foodtech